Crossmark

The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction

Published Online: 2019-01-31

Published Print: 2019-12

Authors

Chen, Xingjuan

Taylor-Nguyen, Natalie N.

Riley, Ashley M.

Herring, B. Paul

White, Fletcher A.

Obukhov, Alexander G. https://orcid.org/0000-0002-3862-6004
Funding

Funding for this research was provided by:

National Heart, Lung, and Blood Institute (R01 HL115140)

National Center for Advancing Translational Sciences (UL1TR001108)

Indiana State Department of Health (19964)

Indiana Clinical and Translational Sciences Institute (PDT 787)
License Information

Text and Data Mining valid from 2019-01-31

Version of Record valid from 2019-01-31
More Information

Article History

Received: 5 August 2018

Accepted: 11 January 2019

First Online: 31 January 2019

Ethics approval

: This study was approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee (protocol # 11284).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current